A Phase I, Open-Label, Dose Escalation Study Evaluating High-Dose Gefitinib (IRESSA®) on Weekly and Twice Weekly Schedules in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
收藏DataCite Commons2025-03-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006136/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study will determine the safety profile and maximum tolerated dose (MTD) of orally administered gefitinib on a weekly and twice weekly schedule.
提供机构：
Vivli
创建时间：
2020-10-30
